Business
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vic
About this update from Biorestorative Therapies, Inc.
[{"type":"image","alt":"BioRestorative Therapies, Inc","displaySize":"","headline":null,"caption":"BioRestorative Therapies, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XBsy.n130Az83pQRRSvCjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992","width":300,"height":122}},"lazy":false},{"type":"text","content":"MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting.","length":627,"tagName":"p"},{"type":"text","content":"No serious adverse events (SAEs) were reported, and there was no dose (40X106 cells) limiting toxicity at 26-104 weeks.","length":119,"tagName":"p"},{"type":"text","content":"The U.S. Food and Drug Association (FDA) is requiring at least a greater than 30% improvement in both Oswestry Disability Index (“ODI”) and Visual Analog Scale (“VAS” ); ongoing clinical data demonstrates trends greater than 30% improvements in both measures. The following is breakdown of the percentage of subjects that had both a greater than 50% improvement in function, as measured by ODI, and a greater than 50% decrease in pain, as measured by VAS:","length":455,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:23%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;","val":[{"type":"text","content":"Week","length":4,"tagName":"p","attribs":{}}]},{"style":"width:77%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;","val":[{"type":"text","content":"Percentage of Subjects with a Greater than 50% improvement in Both ODI...